Highly Accessed Editorial

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

Nicholas C Turner1,2* and Andrew NJ Tutt3

Author Affiliations

1 The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK

2 Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK

3 Breakthrough Breast Cancer Research Unit, Guy's Hospital Campus, Kings Health Partners, London SE1 9RT, UK

For all author emails, please log on.

Breast Cancer Research 2012, 14:115 doi:10.1186/bcr3332


See related research by Byrski et al., http://breast-cancer-research.com/content/14/4/R110

Published: 13 November 2012

Abstract

A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is discussed.